Teclistamab Plus Nirogacestat Elicits Durable Responses in Relapsed/Refractory Myeloma
The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.
Related Articles
Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
FAK Inhibition Emerges as a Potential Complementary Treatment Pathway
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.
Overview of Graft-vs-Host Disease (GvHD)
Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.
Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary Analysis
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients…
NSCLC Clinical Case Simulations for Practicing Oncologists
Welcome to our interactive training module. Please select from below to
Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.